Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;23(3):577-89.
doi: 10.1128/CMR.00063-09.

Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases

Affiliations
Review

Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases

Denise Utsch Gonçalves et al. Clin Microbiol Rev. 2010 Jul.

Abstract

Human T-cell leukemia virus type 1 (HTLV-1), the first human retrovirus to be discovered, is present in diverse regions of the world, where its infection is usually neglected in health care settings and by public health authorities. Since it is usually asymptomatic in the beginning of the infection and disease typically manifests later in life, silent transmission occurs, which is associated with sexual relations, breastfeeding, and blood transfusions. There are no prospects of vaccines, and screening of blood banks and in prenatal care settings is not universal. Therefore, its transmission is active in many areas such as parts of Africa, South and Central America, the Caribbean region, Asia, and Melanesia. It causes serious diseases in humans, including adult T-cell leukemia/lymphoma (ATL) and an incapacitating neurological disease (HTLV-associated myelopathy/tropical spastic paraparesis [HAM/TSP]) besides other afflictions such as uveitis, rheumatic syndromes, and predisposition to helminthic and bacterial infections, among others. These diseases are not curable as yet, and current treatments as well as new perspectives are discussed in the present review.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Geographic distribution of HTLV-1 in countries where the disease is endemic. The stars emphasize high-prevalence areas. The country boundaries shown in the map are not coincidental with the areas of endemicity, reflecting the cluster nature of HTLV infection. (Adapted from reference .)
FIG. 2.
FIG. 2.
MRIs showing thoracic cord atrophy (white arrow) in a patient with HAM/TSP.
FIG. 3.
FIG. 3.
Brain MRI performed with 1.5-T equipment (sagittal T2 weighted; axial FLAIR, T1- and T2-weighted images). (Top) T1-weighted images following venous paramagnetic contrast at three planes. (Bottom) T2-weighted MRI of the brain reveals punctate nodular discrete hyperintense foci without a mass effect in the periventricular and subcortical white matter. These lesions do not increase.

References

    1. Andrade, D. O. 2005. Somatosensitive and motor evoked potentials in HTLV-I associated myelopathy. Arq. Neuropsiquiatr. 63:652-655. - PubMed
    1. Araujo, A. Q. C., and M. T. T. Silva. 2006. The HTLV-1 neurological complex. Lancet Neurol. 5:1068-1076. - PubMed
    1. Bangham, C. R. M., and M. Osame. 2005. Cellular immune response to HTLV-1. Oncogene 24:6035-6046. - PubMed
    1. Bastian, I., Y. Hinuma, and R. R. Doherty. 1993. HTLV-I among Northern Territory Aborigines. Med. J. Aust. 159:12-16. - PubMed
    1. Biggar, R. J., J. Ng, N. Kim, M. Hisada, H. C. Li, B. Cranston, B. Hanchard, and E. M. Maloney. 2006. Human leukocyte antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type I. J. Infect. Dis. 193:277-282. - PubMed

Publication types

MeSH terms

LinkOut - more resources